Tirzepatide, the first drug to activate both GIP and GLP-1 receptors, outperformed semaglutide, dulaglutide, and insulin for blood sugar control and weight loss in type 2 diabetes clinical trials.
Superior to semaglutide 1 mgIn head-to-head phase III trials, tirzepatide beat semaglutide — one of the most effective GLP-1 drugs — for both glycemic control and weight loss in type 2 diabetes
What the researchers found
Tirzepatide (Mounjaro), the first dual GIP/GLP-1 receptor agonist, demonstrated superiority over multiple established diabetes treatments in the phase III SURPASS clinical trial program. Given once weekly by subcutaneous injection, tirzepatide outperformed dulaglutide 0.75 mg, semaglutide 1 mg, and both basal and prandial insulin for both blood sugar control and weight loss in adults with inadequately controlled type 2 diabetes.
The drug showed a favorable safety profile consistent with GLP-1 receptor agonists, with a low risk of clinically significant hypoglycemia and no increased risk of major adverse cardiovascular events. The most common side effects were gastrointestinal — nausea, diarrhea, decreased appetite, and vomiting — and were mostly mild to moderate.
Why it matters
Tirzepatide represents a paradigm shift in diabetes treatment by being the first approved drug to simultaneously activate both GIP and GLP-1 receptors. Its superiority over semaglutide — already considered one of the most effective GLP-1 drugs — in both glycemic control and weight loss establishes a new benchmark for incretin-based therapy. The dual mechanism suggests that combining incretin pathways may be more effective than targeting GLP-1 alone, opening a new chapter in metabolic disease treatment.
The numbers in context
Once-weekly subcutaneous injection · superior to semaglutide 1 mg · superior to dulaglutide 0.75 mg · superior to basal and prandial insulin · low hypoglycemia risk · no increased cardiovascular risk · approved in USA, EU, Japan
How the study worked
This is a published drug review article summarizing evidence from the phase III SURPASS clinical trial program. The SURPASS trials evaluated tirzepatide as monotherapy and as add-on therapy to oral glucose-lowering medications and insulin across multiple randomized controlled trials in adults with type 2 diabetes.
Who was studied
Adults with inadequately controlled type 2 diabetes mellitus across multiple phase III SURPASS trials
What this study cannot tell us
As a review article, this summarizes existing trial data rather than presenting new findings. The SURPASS trials compared tirzepatide to specific doses of competitors (semaglutide 1 mg, dulaglutide 0.75 mg), and comparisons at different doses might yield different results. Long-term safety data beyond the trial periods is still accumulating. The review focuses on type 2 diabetes; weight management approval data (SURMOUNT trials) is addressed separately.
How to read the evidence
This review summarizes data from the SURPASS phase III clinical trial program — large, randomized, controlled trials in humans — representing the highest tier of clinical evidence for drug efficacy and safety.
When this study was published
Published in 2024, this review captures the clinical evidence base at the time of tirzepatide's global approval rollout. The data remains highly current and relevant.
The bigger picture
Tirzepatide has reshaped the metabolic drug landscape. By proving that dual incretin receptor activation outperforms GLP-1 agonism alone, it has validated a new therapeutic approach that pharmaceutical companies are now racing to build on. Beyond diabetes, tirzepatide has since gained approval for weight management (as Zepbound), and trials are exploring its use in heart failure, sleep apnea, and fatty liver disease. It represents the leading edge of a new generation of multi-target peptide therapeutics.
Questions still open
- How does tirzepatide compare to higher doses of semaglutide (2.4 mg) used for weight management?
- What are the long-term cardiovascular outcomes for tirzepatide beyond the trial periods?
- Will triple-agonist peptides targeting GIP, GLP-1, and glucagon receptors outperform tirzepatide's dual mechanism?
Common questions
What makes tirzepatide different from semaglutide (Ozempic/Wegovy)?
What are the main side effects of tirzepatide?
Read the original research
Tirzepatide: A Review in Type 2 Diabetes.
Drugs, 84(2), 227-238
Citation
France, Nicole L; Syed, Yahiya Y. (2024). Tirzepatide: A Review in Type 2 Diabetes.. Drugs, 84(2), 227-238. https://doi.org/10.1007/s40265-023-01992-4